A study was performed to establish whether transrectal ultrasound (TRUS)-based postimplant dosimetry (PID) is both practically feasible and comparable to computed tomography (CT)-based PID, recommended in current published guidelines. In total, 22 patients treated consecutively at a single cancer center with low-dose-rate (LDR) brachytherapy for early-stage prostate cancer had a transrectal ultrasound performed immediately after implant (d0-TRUS) and computed tomography scan 30 days after implant (d30-CT). Postimplant dosimetry planning was performed on both image sets and the results were compared. The interobserver reproducibility of the transrectal ultrasound postimplant dosimetry planning technique was also assessed. It was noticed that there was no significant difference in mean prostate D (136.5Gy and 144.4Gy, p = 0.2197), V (86.4% and 89.1%, p = 0.1480) and V (52.0% and 47.8%, p = 0.1657) for d30-CT and d0-TRUS, respectively. Rectal doses were significantly higher for d0-TRUS than d30-CT. Urethral doses were available with d0-TRUS only. We have shown that d0-TRUS PID is a useful tool for assessing the quality of an implant after low-dose-rate prostate brachytherapy and is comparable to d30-CT PID. There are clear advantages to its use in terms of resource and time efficiency both for the clinical team and the patient.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.meddos.2016.07.001 | DOI Listing |
Vet Med Sci
March 2025
Department of Obstetrics and Gynecology, Faculty of Veterinary Medicine, Siirt University, Siirt, Turkey.
The aim of this study was to determine and compare the diagnostic accuracies of two commercial pregnancy-associated glycoprotein tests, Alertys OnFarm Pregnancy Test (AOPT) and Alertys Milk Pregnancy Test (AMPT), for early pregnancy diagnosis in dairy cattle. Holstein cows (n = 124) were used in the study. Whole blood samples were collected from the jugular vein 28 days after fixed-time artificial insemination (FTAI).
View Article and Find Full Text PDFSurg Technol Int
January 2025
Department of Psychiatry and Narcology, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation.
Pelvic Venous Disorder (PEVD) and May-Thurner syndrome (MTS) represent relatively understudied vascular issues that can significantly impact patients' quality of life. This study aims to evaluate the efficacy of surgical treatment for PEVD and MTS, conduct a comparative analysis of outcomes, and determine the practical significance of different therapeutic approaches. The study was conducted from 2019 to 2022 in Moscow, Russia, encompassing two outpatient clinics.
View Article and Find Full Text PDFJ Clin Med
January 2025
Department of Urology, Laikon General Hospital, National and Kapodistrian University of Athens, 11527 Athens, Greece.
: Multiparametric-Magnetic Resonance Imaging(mp-MRI) presents the ability to detect clinically significant cancer, aiming to avoid biopsy if the results are negative or target an abnormal lesion if a suspected lesion of the prostate is found. Recent guidelines recommend the performance of 12 standard biopsies along with 3 to 5 targeted biopsies in suspected prostate lesions, depending on the size of the prostate lesion. In addition, prostate biopsy can be performed by either the transperineal or the transrectal approach.
View Article and Find Full Text PDFCancers (Basel)
January 2025
Department of Urology, St. Elisabeth Hospital Straubing, 94315 Straubing, Germany.
Background: The relationship between case volume and clinical outcomes is well established for most urological procedures but remains underexplored in prostate ultrasound/MRI fusion biopsy (UMFB). UMFB aims to detect clinically significant prostate cancer (csPCa) by adhering to cancer detection benchmarks for PI-RADS lesions identified via multiparametric MRI (mpMRI). These benchmarks, defined by Ahmed et al.
View Article and Find Full Text PDFBJU Int
January 2025
Faculty of Social Sciences (Health Sciences), Prostate Cancer Research Center, Tampere University, Tampere, Finland.
Objective: To assess the association between prostate-specific antigen (PSA) density (PSAD) and prostate cancer mortality after a benign result on systematic transrectal ultrasonography (TRUS)-guided prostate biopsy.
Patients And Methods: This retrospective study used data from the Finnish Randomised Study of Screening for Prostate Cancer (FinRSPC) collected between 1996 and 2020. We identified men aged 55-71 years randomised to the screening arm with PSA ≥4.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!